Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases [PDF]
International Medical Case Reports JournalIkumi Kashiwagi, Ryota Nonaka, Shotaro Sasaki, Takuto Yamamoto, Kanako Yasuda, Masahiko Shimura Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, JapanCorrespondence: Masahiko Shimura, Department of ...
Kashiwagi I +5 more
doaj +1 more source
Influence of aflibercept on platelet activation profile
, 2018 \ua9 2018 Elsevier Ltd Aflibercept appears to accumulate in systemic circulation following intravitreal injections in therapy of neovascular age-related macular degeneration.
Sobolewska B +9 more
core +8 more sources
Comparative study between the effect of intravitreal injection of Ranibizumab and Aflibercept on macular oedema secondary to branch retinal vein occlusion [PDF]
Al-Azhar International Medical Journal, 2022 Background: Occlusion of retinal veins is a mutual disorder that affect the retina usually occurs when blood clot obstructs a retinal vein. Aim of the work: To compare the effects of Ranibizumab versus Aflibercept intravitreal injections on macular edema
Ahmed Tawfik +2 more
doaj +1 more source
JAMA ophthalmology, 2023 This randomized clinical trial assesses the safety and efficacy of aflibercept, 8 mg, in patients with neovascular age-related macular degeneration.
C. Wykoff +76 more
semanticscholar +1 more source
Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience [PDF]
, 2023 Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials ...
Süleyman Kaynak +11 more
core +1 more source
Translational Oncology, 2019 Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents.
Richard A. Forsgård +8 more
doaj +1 more source
Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
Molecular Therapy: Methods & Clinical Development, 2023 Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in the aging population, with vascular endothelial growth factor (VEGF) playing a key role. Treatment with recombinant anti-VEGFs is the current standard of care; however,
Sharifah Iqball +8 more
doaj +1 more source
Aflibercept clearance through the drainage system in a rat model
International Journal of Retina and Vitreous, 2021 Background As intravitreal anti-VEGF injections became the mainstay of treatment for many retinal diseases, the cause of a secondary sustained elevated intraocular pressure is still unclear.
Yariv Keshet +6 more
doaj +1 more source
ポリープ状脈絡膜血管症の初期治療：ラニビズマブ併用光線力学的療法とアフリベルセプト単独固定療法の比較 [PDF]
, 2019 Purpose: To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial treatment for treatment-naïve polypoidal choroidal ...
米田, 愛
core +1 more source
pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
International Journal of Retina and Vitreous, 2017 Background The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept.
Bianka Sobolewska +3 more
doaj +1 more source